Eliana Merle
Stock Analyst at UBS
(2.06)
# 2,782
Out of 4,784 analysts
75
Total ratings
36.36%
Success rate
-3.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $71.44 | +58.17% | 2 | Feb 20, 2025 | |
| MRNA Moderna | Maintains: Buy | $96 → $78 | $31.12 | +150.64% | 6 | Feb 19, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $8.08 | +370.30% | 3 | Jan 31, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $42 → $109 | $42.72 | +155.15% | 4 | Jan 31, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $5 → $2.2 | $1.81 | +21.55% | 4 | Jan 28, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $65 → $71 | $37.35 | +90.09% | 2 | Jan 8, 2025 | |
| ASND Ascendis Pharma | Initiates: Buy | $196 | $154.68 | +26.71% | 1 | Jan 7, 2025 | |
| TYRA Tyra Biosciences | Initiates: Buy | $28 | $9.77 | +186.59% | 1 | Jan 7, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $3.71 | +223.45% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.91 | +3.26% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $5.32 | +388.72% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $74 | $29.62 | +149.83% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $411 → $441 | $327.87 | +34.50% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $18.95 | +74.14% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $94.95 | +37.97% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $2 | $1.22 | +63.93% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $24.27 | +241.99% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $268.46 | +7.28% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $35.11 | +33.87% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $2.91 | +71.82% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $2.92 | +516.44% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $12.47 | +236.81% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $2.98 | +504.03% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.17 | +583.76% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.10 | +331.37% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.83 | +500.26% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.43 | +89.80% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $7.59 | +1,520.55% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $25.46 | +426.32% | 3 | Aug 19, 2020 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $71.44
Upside: +58.17%
Moderna
Feb 19, 2025
Maintains: Buy
Price Target: $96 → $78
Current: $31.12
Upside: +150.64%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $8.08
Upside: +370.30%
Akero Therapeutics
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $42.72
Upside: +155.15%
Zentalis Pharmaceuticals
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.81
Upside: +21.55%
Revolution Medicines
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $37.35
Upside: +90.09%
Ascendis Pharma
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $154.68
Upside: +26.71%
Tyra Biosciences
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $9.77
Upside: +186.59%
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $3.71
Upside: +223.45%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.91
Upside: +3.26%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $5.32
Upside: +388.72%
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $29.62
Upside: +149.83%
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $327.87
Upside: +34.50%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $18.95
Upside: +74.14%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $94.95
Upside: +37.97%
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $1.22
Upside: +63.93%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $24.27
Upside: +241.99%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $268.46
Upside: +7.28%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $35.11
Upside: +33.87%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $2.91
Upside: +71.82%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $2.92
Upside: +516.44%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $12.47
Upside: +236.81%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.98
Upside: +504.03%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.17
Upside: +583.76%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $5.10
Upside: +331.37%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.83
Upside: +500.26%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $8.43
Upside: +89.80%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $7.59
Upside: +1,520.55%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $25.46
Upside: +426.32%